🔎 Trials Near Me

Beranda › PPOK › South Carolina

Uji klinis PPOK di South Carolina

14 studi untuk PPOK mencari peserta di lokasi di South Carolina.

Kota di South Carolina

Teks studi resmi (Bahasa Inggris)

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  • Research Site, Anderson
  • Research Site, Charleston
  • Research Site, Gaffney
  • dan 2 lainnya
Menerima pesertaFase 3
Usia 40 hingga 80 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06283966

To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

  • Clinical Research of Rock Hill, Rock Hill
Menerima pesertaFase 2
Usia 40 hingga 85 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07684820

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

  • AnMed Oglesby Center- Site Number : 8400074, Anderson
  • MD First Research - Lancaster- Site Number : 8400102, Lancaster
Menerima pesertaFase 3
Usia 40 hingga 80 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07190209

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  • Research Site, Lancaster
  • Research Site, Spartanburg
Menerima pesertaFase 2
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07082738

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

  • Research Site, Anderson
  • Research Site, Columbia
  • Research Site, Gaffney
  • dan 2 lainnya
Menerima pesertaFase 3
Usia 40 hingga 80 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06878261

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

  • Research Site, Rock Hill
Menerima pesertaFase 3
Usia 40 hingga 80 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06883305

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  • Bogan Sleep Consultants, LLC, Columbia
  • Velocity Clinical Research, Gaffney, Gaffney
  • Clinical Research of Rock Hill, Rock Hill
  • dan 1 lainnya
Menerima pesertaFase 2/3
Usia 35 hingga 80 · Semua jenis kelamin · Diperbarui 31 Agu 2026 · NCT07363694

STRIVE Post-Market Registry Study

  • AnMed Health, Anderson
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT04302272

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

  • GSK Investigational Site, Greenville
  • GSK Investigational Site, Rock Hill
Menerima pesertaFase 3
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 28 Jul 2026 · NCT07177339

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

  • GSK Investigational Site, Spartanburg
  • GSK Investigational Site, Union
Menerima pesertaFase 3
Usia 40 hingga 80 · Semua jenis kelamin · Diperbarui 9 Apr 2026 · NCT06961214

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

  • GSK Investigational Site, Rock Hill
Menerima pesertaFase 3
Usia 40 hingga 80 · Semua jenis kelamin · Diperbarui 8 Okt 2025 · NCT06959095

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

  • Medical University of South Carolina (MUSC), Charleston
  • McLeod Health, Florence
Menerima pesertaStudi observasional
Usia 50 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2025 · NCT06122077

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.